ArthroCare Announces Participation in Investor Conference

Mon Dec 31, 2012 4:00pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121231:nBw315154a

AUSTIN, Texas--(Business Wire)--
ArthroCare Corp. (NASDAQ: ARTC), a leader in developing state-of-the-art,
minimally invasive surgical products, announced today participation in an
upcoming investor conference, as detailed below. 

On Tuesday, January 8, 2013 ArthroCare will present during the 31st Annual J.P.
Morgan Healthcare Conference. David Fitzgerald, President and Chief Executive
Officer will deliver the business presentation. Please see the conference
details below. 

31st Annual J.P. Morgan Healthcare Conference

* Date: Tuesday, January 8, 2013 
* Time: 2:30 p.m. PT 
* Location: San Francisco, CA

The presentation will be webcast live and can be accessed on ArthroCare's
website at www.arthrocare.com. The webcast will remain available for 30 days
following the presentation. 

ABOUT ARTHROCARE

ArthroCare develops and manufactures surgical devices, instruments, and implants
that strive to enhance surgical techniques as well as improve patient outcomes.
Its devices improve many existing surgical procedures and enable new minimally
invasive procedures. Many of ArthroCare`s devices use its internationally
patented CoblationĀ® technology. This technology precisely dissolves target
tissue and limits damage to surrounding healthy tissue. ArthroCare also develops
surgical devices utilizing other patented technology including its OPUSĀ® line of
fixation products as well as re-usable surgical instruments. ArthroCare is
leveraging these technologies in order to offer a comprehensive line of surgical
devices to capitalize on a multi-billion dollar market opportunity across
several surgical specialties, including its two core product areas consisting of
Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine,
wound care, urology and gynecology. 

FORWARD-LOOKING STATEMENTS

The information provided herein includes forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Statements that are not historical facts are forward-looking statements.
Forward-looking statements are based on beliefs and assumptions by management
and on information currently available to management. Forward-looking statements
speak only as of the date they are made, and the Company undertakes no
obligation to update any of them publicly in light of new information or future
events. Additional factors that could cause actual results to differ materially
from those contained in any forward-looking statement include, without
limitation: the resolution of litigation pending against the Company; the impact
upon the Company`s operations of legal compliance matters which may require
improvement and remediation; the ability of the Company to control expenses
relating to legal or compliance matters; the Company`s ability to remain current
in its periodic reporting requirements under the Exchange Act and to file
required reports with the Securities and Exchange Commission on a timely basis;
the results of the investigation being conducted by the United States Department
of Justice; the impact on the Company of additional civil and criminal
investigations by state and federal agencies and civil suits by private third
parties involving the Company`s financial reporting and its previously announced
restatement and its insurance billing and healthcare fraud-and-abuse compliance
practices; the results of the civil investigation by the Department of Justice
related to the Civil Investigative Demand we received arising under the False
Claims Act; the possibility that the Department of Justice could institute civil
proceedings against us, based on the results of the investigation related to the
Civil Investigative Demand; the risk that we could be subject to qui tam suits
involving the False Claims Act; the possibility that the Department of Justice
could institute a criminal enforcement action against us based on the results of
the civil investigation related to the Civil Investigative Demand;the resolution
of any litigation related to the civil investigation; the ability of the Company
to attract and retain qualified senior management and to prepare and implement
appropriate succession planning for its Chief Executive Officer; general
business, economic and political conditions; competitive developments in the
medical devices market; changes in applicable legislative or regulatory
requirements; the Company`s ability to effectively and successfully implement
its business strategies, and manage the risks in its business; and the reactions
of the marketplace to the foregoing.

ArthroCare Corp.
Misty Romines, 512-391-3902 



Copyright Business Wire 2012
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.